Ordering Recommendation

Secondary diagnostic testing for myasthenia gravis when first-line diagnostic tests are negative. Screen for presence of thymoma in patients with myasthenia gravis.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation

Plain Red or Serum Separator Tube (SST).

Specimen Preparation

Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min. 0.5 mL)

Storage/Transport Temperature

Refrigerated. Also acceptable: Frozen

Unacceptable Conditions

Moderately icteric specimens.


After separation from cells: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month (avoid multiple freeze/thaw cycles)


Semi-Quantitative Enzyme-Linked Immunosorbent Assay




1-8 days

Reference Interval

Test Number
Reference Interval
  Titin Antibody 0.45 IV or less

Interpretive Data

The presence of titin antibody is associated with late onset of myasthenia gravis (MG) and a variable risk for thymoma. Titin antibody may be detected in 20-40 percent of all patients with MG; higher frequency in older population as a whole.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Component Interpretation
Titin Antibody 0.00-0.45 IV: Negative
0.46-0.71 IV: Indeterminate
0.72 IV or greater: Positive

Compliance Category

Laboratory Developed Test (LDT)


Hotline History


CPT Codes



Component Test Code* Component Chart Name LOINC
2005637 Titin Antibody 100371-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.


  • Tintin Ab
Titin Antibody